Compare BridgeBio Pharma Inc (BBIO) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Oracle Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Oracle Corporation trades at $146.49 (market cap $423.49B). The key difference: Oracle Corporation is far larger — about 25.5× BridgeBio Pharma Inc's market cap, and Oracle Corporation pays a 1.36% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ORCL | |
|---|---|---|
Market Cap | $16.61B | $423.49B |
Sector | Health | Technology |
52-Week High | $90.17 | $328.33 |
52-Week Low | $47.29 | $114.99 |
Enterprise Value | $18.16B | $552.74B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Oracle (ORCL) trades at $145.45, down 1.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.11 beating expectations of $1.96, and fundamentals show robust revenue growth, reaching $57.4 billion in 2025, and high profitability with a net margin of 25.37%. Recent news highlights Oracle's AI infrastructure growth and a legal investigation into insider conduct.
Oracle's outlook is positive due to AI-driven demand and consistent earnings outperformance, supported by a consensus analyst price target of $253.63. Key risks include high valuation multiples, rising debt levels, and competitive pressures in cloud services. The stock offers growth potential but requires monitoring of execution risks and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
